Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01862328 · ClinicalTrials.gov registry record · Phase 1

Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel in Participants With Solid Tumors

A Phase 1 study of Solid Tumors, sponsored by Millennium Pharmaceuticals.

Completed
Registry status
Phase 1
Development phase
64
Enrollment target
6
Study locations

NCT01862328 is a Phase 1 study of Solid Tumors that has completed, run by Millennium Pharmaceuticals. The registered enrollment target is 64 participants, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (77% lower). The trial reports 6 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01862328, a Phase 1 study of Solid Tumors, has completed, sponsored by Millennium Pharmaceuticals.

COMPLETED
Registry status
Phase 1
Development phase
64 participants
Enrollment target
6
Study locations

Study Summary

The purpose of this study is to establish the maximum tolerated dose (MTD) and assess the safety and tolerability of MLN4924 (pevonedistat) in combination with docetaxel, paclitaxel and carboplatin, and gemcitabine in participants with solid tumors.

Conditions Studied

Solid Tumors

Interventions

  • DRUG Carboplatin
  • DRUG Docetaxel
  • DRUG Paclitaxel
  • DRUG Gemcitabine
  • DRUG MLN4924

Study Locations (6)

Georgia

  • - Atlanta

Missouri

  • - St Louis

North Carolina

  • - Chapel Hill

Ohio

  • - Cleveland

Pennsylvania

  • - Philadelphia

Tennessee

  • - Nashville

Trial Details

FieldValue
Enrollment Target 64 participants
Start Date 2013-06-10
Est. Completion 2018-05-21
Phase Phase 1

Sponsor

Millennium Pharmaceuticals

135 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01862328

The ClinicalTrials.gov registry entry for NCT01862328 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (77% lower). The listed sponsor is Millennium Pharmaceuticals, which has 135 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Solid Tumors appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.

NCT01862328 reports 6 study locations spanning 6 distinct geographic areas - top geographies include Georgia, Missouri, North Carolina.

Frequently Asked Questions

What is clinical trial NCT01862328 about?

NCT01862328 is a clinical study titled "Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel in Participants With Solid Tumors". The purpose of this study is to establish the maximum tolerated dose (MTD) and assess the safety and tolerability of MLN4924 (pevonedistat) in combination with docetaxel, paclitaxel and carboplatin, and gemcitabine in participants with solid tumors.

What is the current status of trial NCT01862328?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2013-06-10. Estimated completion is 2018-05-21.

What conditions does trial NCT01862328 study?

This clinical trial studies the following conditions: Solid Tumors.

What interventions are being tested in trial NCT01862328?

The interventions under investigation include: Carboplatin (DRUG), Docetaxel (DRUG), Paclitaxel (DRUG), Gemcitabine (DRUG), MLN4924 (DRUG).

Who is sponsoring clinical trial NCT01862328?

This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01862328 being conducted?

This trial has 6 study locations across Georgia, Missouri, North Carolina, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Solid Tumors

All registered trials for this condition

Georgia

All trials with a study site in Georgia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.